First-in-Human Results of SynGEM Demonstrate that the RSV Vaccine Is Well-Tolerated and Capable of I
SynGEM a needle-free nasal spray vaccine against respiratory syncytial virus * SynGEM shown to be safe and immunogenic in healthy adults * SynGEM the first non-replicating intranasal RSV subunit vaccine to induce persistent antibody responses in humans Groningen, the Netherlands, March 6, 2019 – Virtuvax B.V. and the trustee of biotech company Mucosis B.V., Mr. Holtz LLM today announce the results of a first-in-human study of the intranasal Respiratory Syncytial Virus (RSV) v